INVO Bioscience

137 articles with INVO Bioscience

• INVO Bioscience Enters Distribution Agreement for Taiwan

  1/5/2023

  INVO Bioscience, Inc. announced it has entered an exclusive distribution agreement with Ming Mei Technology Co. Ltd for Taiwan.

• INVO Bioscience Engages Nationally Recognized Physician for New Tampa-based INVO Center

  1/3/2023

  INVO Bioscience, Inc. announced it has signed an agreement with Shelly W. Holmström, M.D. FACOG, to serve as the physician operator for the Company's soon to be opened Tampa, Florida INVO Center.

• First Baby Born in Malaysia Utilizing Innovative INVOcell Assisted Reproductive Technology

  11/30/2022

  INVO Bioscience, Inc. announced the birth of the first baby in Malaysia utilizing the INVOcell solution.

• INVO Bioscience Reports Third Quarter 2022 Financial Results

  11/14/2022

  INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced financial results for the third quarter ended September 30, 2022 and provided a business update.

• INVO Bioscience to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022

  11/10/2022

  INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the IVC procedure it enables, will report financial results for its third quarter 2022, ended September 30, 2022, after the market close on Monday, November 14, 2022.

• INVO Bioscience Highlights INVOcell Progress From the 2022 American Society for Reproductive Medicine (ASRM) Congress & Expo

  11/1/2022

  INVO Bioscience, Inc. (NASDAQ: INVO) today announced a successful showcasing of INVOcell at last week's 2022 Scientific Congress & Expo of the American Society for Reproductive Medicine (ASRM) held on October 22-26, 2022 in Anaheim, California.

• INVOcell Review Published in Current Opinion in Obstetrics and Gynecology

  10/21/2022

  INVO Bioscience, Inc. today announced the publication of a review discussing existing literature and current use of intravaginal culture (IVC) as an option for patients seeking fertility therapies.

• INVO Bioscience to Exhibit at the 2022 American Society for Reproductive Medicine (ASRM) Congress & Expo

  10/17/2022

  INVO Bioscience, Inc. (NASDAQ: INVO) today announced the company will exhibit at the 2022 Scientific Congress & Expo of the American Society for Reproductive Medicine (ASRM).

• Dr. Sue Ellen Carpenter of INVO Bioscience's Atlanta-based INVO Center - Bloom Fertility - Named Top Doctor by Castle Connolly

  9/22/2022

  INVO Bioscience, Inc. today announced that Dr. Sue Ellen Carpenter of Bloom Fertility, the Company's Atlanta-based INVO Center, was named a recipient of the Castle Connolly Top Doctor Award for 2023.

• INVOcell Launched in Malaysia by Advanced Reproductive Centre, Hospital Canselor Tuanku Muhriz

  8/25/2022

  INVO Bioscience, Inc. announced that Advanced Reproductive Centre, Hospital Canselor Tuanku Muhriz, formally known as Hospital Universiti Kebangsaan Malaysia, based in Kuala Lumpur, Malaysia, is making IVC available for their patients.

• INVO Bioscience Reports Second Quarter 2022 Financial Results

  8/15/2022

  INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), today announced financial results for the second quarter ended June 30, 2022 and provided a business update.

• INVO Bioscience to Report Second Quarter 2022 Financial Results on Monday, August 15, 2022

  8/4/2022

  INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the IVC procedure it enables, will report financial results for its second quarter 2022, ended June 30, 2022, after the market close on Monday, August 15, 2022.

• INVO Bioscience Announces "Get to Know INVOcell" - a Series of Facebook Live Events Supporting Access to Affordable Fertility Treatment

  7/7/2022

  INVO Bioscience, Inc. announced that Dr. Sue Ellen Carpenter of Bloom Fertility, an INVO Center in Atlanta, will be hosting "Get to Know INVOcell" - a Facebook Live Event on July 7, 2022 at 7 PM ET.

• INVO Signs Distribution Agreement with Onesky Holding Limited for Mainland China

  5/16/2022

  INVO Bioscience, Inc. announced it has entered an exclusive distribution agreement with Onesky Holdings Limited for Mainland China.

• INVO Bioscience Reports First Quarter 2022 Financial Results

  5/16/2022

  INVO Bioscience, Inc. announced financial results for the first quarter ended March 31, 2022 and provided a business update.

• INVO Bioscience to Report First Quarter 2022 Financial Results on Monday, May 16, 2022

  5/9/2022

  INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the IVC procedure it enables, will report financial results for its first quarter 2022, ended March 31, 2022, after the market close on Monday, May 16, 2022.

• INVO Selects Kansas City as additional INVO Center Location

  4/14/2022

  INVO Bioscience, Inc., a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture procedure it enables, announced plans to open an INVO Center in Kansas City, Missouri.

• INVO Bioscience to Participate in the Lytham Partners Spring 2022 Investor Conference

  4/4/2022

  INVO Bioscience, Inc. announced that it will be participating in the Lytham Partners Spring 2022 Investor Conference taking place virtually on April 4-7, 2022.

• INVO Bioscience Reports 2021 Financial Results

  3/31/2022

  INVO Bioscience, Inc. announced financial results for the year ended December 31, 2021, and provided a business update.

• INVO Bioscience to Report Fourth Quarter and Fiscal Year 2021 Financial Results on Thursday, March 31, 2022

  3/24/2022

  INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the IVC procedure it enables, will report financial results for its fourth quarter and fiscal year 2021, ended December 31, 2021.